All In Biotech

Drug Trial Radar · NCT03810313

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Last checked: Nov 20, 2026Latest source record: Jan 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 493 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

493

Actual

Start

Jul 3, 2019

Primary completion

Jul 26, 2021

Study completion Jul 26, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Conditions

  • Central Retinal Vein Occlusion

Interventions

  • Brolucizumab 6 mgDrug

    Solution for injection (intravitreal use)

  • Aflibercept 2 mgDrug

    Solution for injection (Intravitreal use)

  • Sham injectionOther

    Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24Time frame: Baseline, Week 24

Locations

120 sites in 20 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Mountain View, California

  • Novartis Investigative Site

    Santa Barbara, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    New Albany, Indiana

  • Novartis Investigative Site

    Leawood, Kansas

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    Stoneham, Massachusetts

  • Novartis Investigative Site

    Minneapolis, Minnesota

  • Novartis Investigative Site

    Reno, Nevada

  • Novartis Investigative Site

    Bloomfield, New Jersey

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Monroeville, Pennsylvania

  • Novartis Investigative Site

    Memphis, Tennessee

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Abilene, Texas

  • Novartis Investigative Site

    Arlington, Texas

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Bellaire, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    Albury, New South Wales, Australia

  • Novartis Investigative Site

    Parramatta, New South Wales, Australia

  • Novartis Investigative Site

    Strathfield, New South Wales, Australia

  • Novartis Investigative Site

    Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Hobart, Tasmania, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Québec, Canada

  • Novartis Investigative Site

    Calgary, Alberta, Canada

  • Novartis Investigative Site

    London, Ontario, Canada

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.